THERACLION SA announced at the 2022 AVLS congress in New Orleans, Louisiana (US), on October 14(th), that the final patient enrolled in the first SONOVEIN(R) study in the United States has been treated. Finalized enrollment in the US study on echotherapy for varicose veins In total, 20 patients were enrolled in this clinical trial approved by the FDA in early 2022. Conducting the clinical trial are Dr. Steve Elias, principal investigator, Dr. Nicos Labropoulos, and Dr Antonios Gasparis, all three internationally recognized vein specialists with more than 30 years of experience each.

SONOVEIN(R) HD utilizes a robotic platform that integrates the best-in-class, high-definition MACH30 10-12Mhz ultrasound imaging system with high intensity focused ultrasound to obliterate the source of venous reflux completely non-invasively. Encouraging early results presented at the 2022 AVLS congress Early results were presented at the 36(th) American Vein & Lymphatic Society (AVLS) Annual Congress in New Orleans, Louisiana, on October 14(th) . Dr. Elias highlighted that 19/20 (95%) of cases had no reflux at one week interval.

The completion of the study was three months interval, 10 out of 10 had no reflux. There were no reported adverse events. All patients were treated without local or tumescent anesthesia.

No post procedure compression was utilized.Dr Elias shared during the congress that SONOVEIN(R) HD enabled faster treatment than previous generations and that he 'only needed his pencil and his ultrasound gel' to treat his patients.